NX-1607 is a potent and selective Casitas B-lineage lymphoma-b (Cbl-b) E3 ubiquitin ligase inhibitor. It affects T cell receptor (TCR) signaling by blocking Cbl-b-mediated ubiquitination of target proteins, effectively promoting T cell activation and enhancing anti-tumor immunity.
NX-1607 (Cbl-b-IN-3) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for NX-1607 (Cbl-b-IN-3) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.